Strategic Partnerships to Deliver CureVac’s COVID-19 Ambition

Webcast Presentation, February 5, 2021
Forward-Looking Statements

The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation of CureVac N.V. (the “company”) contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections of the company regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the company’s vaccine candidate and the company’s strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” or “expect,” “may,” “will,” “would,” “could,” “potential,” “intend,” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company’s performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company’s industry, the effects of the COVID-19 pandemic on the company’s business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

For further information, please reference the company’s reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.
## Deliver on the Potential of the Curevac Technology to Create Sustainable Value

### CureVac’s Strategic COVID-19 Partnerships, February 2021

<table>
<thead>
<tr>
<th>Category</th>
<th>First-Gen Vaccines</th>
<th>Second-Gen Vaccines</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original Spike Protein</td>
<td>Bayer</td>
<td>GSK</td>
</tr>
<tr>
<td>Mutated Spike Proteins</td>
<td>Cooperation and Services Agreement</td>
<td>Co-Development Partnership</td>
</tr>
<tr>
<td>Combination Vaccines</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Short-term Value Creation
- Government orders

### Mid- and Long-term Value Creation
- GSK partnership and CureVac DACH commercial operations

### Key Points:
- **Original Spike Protein**
  - Bayer: Cooperation and Services Agreement
- **Mutated Spike Proteins**
  - GSK: Co-Development Partnership
- **Combination Vaccines**
  - R&D collaboration

---

DACH: Germany, Austria, Switzerland
Execution Power Provided by Bayer’s Large-Pharma Infrastructure

Collaboration and Services Agreement
Announced January 7, 2021

- Expertise and Infrastructure
  Adding operational knowledge, broad international reach and regional access to support global supply of CureVac’s CVnCoV

- Product Development Support
  Adding muscle in areas such as clinical operations, regulatory affairs, pharmacovigilance, and supply chain performance

- Key Territory Operations
  Adding country support for EU member states and beyond

CureVac to be Market Authorization Holder, option for Bayer in other markets outside the EU
World-Leading Vaccine Expertise with GSK for next generation mRNA COVID-19 vaccines

Co-Development Partnership
Announced July 20, 2020, extended on January 3, 2021

- **Vaccine Development Expertise**
  
  Joint development of 2\textsuperscript{nd} generation mRNA vaccines including monovalent and multivalent approaches to address emerging variants in one vaccine.

  Joint efforts to address new and future variants to stay one step ahead of the pandemic with resources to research, development and manufacturing.

  Focus on developing post-pandemic vaccines.

- **Commercialization Roles**

  **GSK to be Marketing Authorization Holder** with exclusive rights for development, manufacturing, and commercialization.

  CureVac to retain three commercial areas: Germany, Austria, Switzerland.
At the Forefront of Science and Surveillance with the UK Government

Research and Development Collaboration
Announced February 5, 2021

- Scientific Variant Assessment and Selection
  Assessing novel vaccines for SARS-CoV-2 variants and vaccine approaches against selected mutations

  Building on the VTF leading scientific expertise

  Mitigate the effects of the current pandemic, help manage and prepare for future outbreaks

- Clinical trial execution

  Clinical studies are expected to be undertaken in the UK towards securing marketing authorizations for jointly selected vaccines

- Manufacturing and distribution

  Technology transfer by CureVac

  Resulting vaccines expected to be manufactured and distributed in the UK and its overseas and dependent territories
Commercial Overview and Roles

- **Service Agreement**
  - MAH:
    - **CureVac** in the EU
    - **Option for Bayer** in other geographies

- **Upfront:** €75 m
- **Milestone:** €75 m
- Development cost/profit split: **50:50**
- MAH: **GSK**

- **Each party carries own R&D costs**
- **UK to purchase 50m doses**
- MAH: **CureVac**

---

**CureVac’s Strategic COVID-19 Partnerships, February 2021**

MAH: Market Authorization Holder
Scaling-up a Broad and High-Performing Manufacturing Network

- Network of highly experienced CDMO partners for key manufacturing steps
- Flexible network expected to serve a variable demand, while mitigating supply chain risks
- Expected network annual output of up to 300m doses in 2021 and up to 1billion doses in 2022

RNA Printer™
Fully automated, mobile
GMP-grade manufacturing
- Pandemic preparedness
- Customized therapeutics
- Clinical development
Key Messages

Three key partnerships to deliver on our COVID-19 ambitions in first and second generation vaccines

The Bayer collaboration represents a key success factor for clinical and commercial roll out and delivery of CVnCoV and derived first generation vaccine candidates

The GSK partnership is a strong value driver for our strategy to address both current and emerging COVID-19 variants through second-generation vaccines

The UK government collaboration is a central enabler for the spectrum of both, first and second generation COVID-19 vaccines as a source for highest quality scientific input

Our manufacturing capacities including the RNA Printer will continue to grow and we were able to update our 2022 capacity to 1 billion doses
Thank you for your interest

CureVac
www.curevac.com